Hancock, MD, Oct. 17, 2016 - PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the
This presentation is the property of its rightful owner.
Sponsored Links
1 / 2

PetLife Pharmaceuticals is Pleased to Announce the Completion of the N PowerPoint PPT Presentation


  • 14 Views
  • Uploaded on
  • Presentation posted in: Pets / Animals

Hancock, MD, Oct. 17, 2016 - PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and Nutraceuticals for pets, has completed the corporate website overhaul as FDA/CVM submission and testing nears.

Download Presentation

PetLife Pharmaceuticals is Pleased to Announce the Completio...

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Petlife pharmaceuticals is pleased to announce the completion of the n

Hancock, MD, Oct. 17, 2016 - PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the

"Company"), a developer of a new generation of high potency veterinary cancer medications

and Nutraceuticals for pets, has completed the corporate website overhaul as FDA/CVM

submission and testing nears.

In conjunction with the hiring of InnoVision, rebranding of Escozine for Pets as Vitalzul™

and in preparation for the FDA/CVM process, management felt a clean, modern design

website with easy navigation and helpful tools for pet owners, investors and veterinarians was

warranted.

Please

check

out

the

http://www.petlifepharma.com/

new

PetLife

Pharmaceutical

website:

PetLife’s website offers a complete overview of the company, including corporate news,

stock price and chart, as well as testimonials, vet endorsements and details on Vitalzul™:

-Science behind Vitalzul™

-The Patent

-Oncological treatment including post FDA/CVM product lines

-PetLife’s Nutraceutical lines

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

About PetLife Pharmaceuticals, Inc:

PetLife Pharmaceuticals (OTCQB: PTLF) (http://www.PetLifePharma.com) is a registered

US Veterinary Pharmaceutical company, incorporated in 2012.

PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive

Nutraceuticals and prescription medication, Vitalzul™, to the world of veterinary oncology --

with the ultimate goal of preventing cancer and extending the life of pets suffering from

cancer while improving their quality of life. In the US alone, consumer spending on domestic

companion animals reached over $60 billion in 2015 with over $29 billion spent on

veterinary care and medications.

Safe Harbor:

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife

encourages those interested in our Company to rely only on information included in our

filings with the United States Securities and Exchange Commission which can be found at

www.sec.gov. Statements released by the Company that are not purely historical are forward-

looking within the meaning of the "Safe Harbor" provisions of the Private Securities


Petlife pharmaceuticals is pleased to announce the completion of the n

Litigation Reform Act of 1995, including statements regarding the company's expectations,

hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking

statements involve risk and uncertainties that may affect the Company's business prospects

and performance. The Company's actual results could differ materially from those in such

forward-looking statements. Risk factors include but are not limited to general economic,

competitive, governmental, and technological factors as discussed in the Company's filings

with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any

responsibility to update the forward-looking statements contained in this release.

Address: 38 West Main Street

City: Hancock

State: MD

Country: USA

Zip code: 21750

Phone: (844) 473-8543

Email ID: [email protected]

Website: http://www.petlifepharma.com

Twitter: https://twitter.com/PetLife_Pharma

Facebook: https://www.facebook.com/PetLifePharmaceuticals

Linkedin.com: https://www.linkedin.com/company/petlife-pharmaceuticals

Pinterest.com: https://www.pinterest.com/petlifepharma/

Plus.google.com: https://plus.google.com/112539165716220754089/about

Instagram.com: https://www.instagram.com/petlifepharma/

Youtube.com: https://www.youtube.com/channel/UC8OdShp1H3Aa1TMXwXWdebQ

Press Release: http://finance.yahoo.com/quote/ptlf?ltr=1


  • Login